WW International reported third‑quarter 2025 results that combined a 10.8% year‑over‑year decline in total revenue with a 35% jump in clinical subscription revenue, underscoring the company’s pivot toward integrated weight‑health solutions. Total revenue reached $172 million, down from $192.9 million in Q3 2024, while clinical revenue climbed to $26 million, the highest level in the company’s history.
The revenue drop was largely driven by a 10% decline in the behavioral segment, where subscriber acquisition has slowed amid intensified competition and pricing pressure. In contrast, the clinical arm, which includes prescription medication access and medical‑grade programs, grew 35.3% year‑over‑year, offsetting the weakness in the core behavioral business and supporting the company’s long‑term growth strategy.
WW posted a net loss of $58 million, a loss margin of 33.4%. The loss was amplified by a $53 million income‑tax expense charge, a one‑time item that reflects the company’s post‑bankruptcy tax restructuring. Earnings per share fell to $‑0.44, missing consensus estimates of $0.51 or $0.12, a miss largely attributable to the tax charge and the continued need for restructuring costs.
Adjusted EBITDA for the quarter was $43 million, a margin of 24.9% that represents a 1.5‑percentage‑point improvement over the prior year. The margin expansion is driven by disciplined cost management and a shift toward higher‑margin clinical revenue, which carries lower variable costs than the behavioral segment.
Management raised its full‑year 2025 guidance to a revenue range of $695 million to $700 million and an adjusted EBITDA range of $145 million to $150 million, the higher end of the previously issued ranges. The upgrade reflects confidence in the continued acceleration of clinical revenue, the effectiveness of cost‑saving initiatives, and the company’s strengthened balance sheet after emerging from Chapter 11 bankruptcy.
Investor reaction was positive, with the stock rising 13% in after‑hours trading. The rally was driven by the strong clinical growth, the company’s debt reduction of over 70% during the bankruptcy process, and the higher‑end guidance that signals management’s optimism about future performance.
CEO Tara Comonte emphasized the company’s new era: “WeightWatchers is entering a new era, uniquely positioned at the intersection of medical innovation and behavioral science, to lead this rapidly evolving weight‑health market.” CFO Felicia DellaFortuna added that while the behavioral business remains pressured, the 35% growth in clinical revenue and a 24.9% adjusted EBITDA margin demonstrate disciplined cost control and a path to sustainable growth.
The results highlight a mixed picture: a post‑bankruptcy balance sheet that has cut debt by more than $1 billion, a robust clinical growth engine, and ongoing headwinds in the behavioral segment. The company’s strategic focus on integrating medical and behavioral solutions positions it well for long‑term resilience, but continued subscriber acquisition challenges in the core business will require sustained investment and innovation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.